Diuretic Effects of Subcutaneous Furosemide in Human Volunteers: A Randomized Pilot Study

Annals of Pharmacotherapy

Volumn 38, Issue 4, 2004, Pages 544-549

  Verma, Arun K ^a   Da Silva, Jack H ^b   Kuhl, David R ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

Furosemide; Subcutaneous

Indexed keywords

FUROSEMIDE; SODIUM CHLORIDE;

ADULT; ARTICLE; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIETARY INTAKE; DIURESIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EDEMA; FEMALE; FLUID INTAKE; HEART FAILURE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; INJECTION PAIN; MALE; MICTURITION; NORMAL HUMAN; OUTCOMES RESEARCH; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM URINE LEVEL; URINE VOLUME;

ADULT; AGED; BLOOD UREA NITROGEN; CREATININE; CROSS-OVER STUDIES; DIURESIS; DIURETICS; DOUBLE-BLIND METHOD; FEMALE; FUROSEMIDE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NATRIURESIS; PILOT PROJECTS;

EID: 1642568269     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D332     Document Type: Article

References (26)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003;289:2560-72.
2. Insua JT, Sacks HS, Lau TS, Lau J, Reitman D, Pagano D, et al. Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 1994;121:355-62.
3. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldmanmd AM, Francis GS, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 2001;104:2996-3007.
4. Sica D, Gehr TW. Diuretic combinations in refractory edema states. Clin Pharmacokinet 1996;30:229-49.
5. Suki WN. Use of diuretics in chronic renal failure. Kidney Int Suppl 1997;59:S33-5.
6. Anderson PO, Knoben JE, Troutman W, eds. Handbook of clinical drug data. 10th ed. New York: McGraw-Hill, 2002:717-20.
7. Brion LP, Primhak RA, Yong W. Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2000;2:CD001694.
8. Echazarreta AL, Gomez FP, Ribas J, Achaval M, Barbera JA, Roca J, et al. Effects of inhaled furosemide on platelet-activating factor challenge in mild asthma. Eur Respir J 1999;14:616-21.
9. Ansel HC, Allen LV Jr, Popovich NG. Pharmaceutical dosage forms and drug delivery systems. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 1999:60-100.
10. Robinson DH, Narducci WA, Ueda CT. Drug delivery and administration. In: DiPiro JT, Talbert RL, Hayes PE, Yee GC, Malzke GR, Posey ML, eds. Pharmacotherapy: a pathophysiologic approach. Norwalk, CT: Appleton and Lange, 1993:32-55.
11. Franklin MR, Franz DN. Drug absorption, action, and disposition. In: Gennaro AR, Der Marderosian AH, Hanson GR, Medwick T, Popovich NG, Schnaare RL, et al., eds. Remington: the science and practice of pharmacy. 20th ed. Philadelphia: Lippincott Williams & Wilkins, 2000:1098-127.
12. Storey P, Hill HH, St. Louis RH, Tarver EE. Subcutaneous infusions for control of cancer symptoms. J Pain Symptom Manage 1990;5:33-41.
13. Newton M, Newton DW, Fudin J. Reviewing the "big three injection routes." Nursing 1992;22:34-41.
14. Ansel HC, Allen LV Jr, Popovich NG. Pharmaceutical dosage forms and drug delivery systems. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 1999:101-41.
15. Lukacsko P. A guide to the parenteral management of moderate to severe pain. Hosp Pharm 1987;22:361-5.
16. Feldman S. Biopharmaceutic factors influencing drug availability. In: Turco S, King RE, eds. Sterile dosage forms: their preparation and clinical preparation. Philadelphia: Lea & Febiger, 1987:101-15.
17. Herndon CM, Fike DS. Continuous subcutaneous infusion practices of United States hospices. J Pain Symptom Manage 2001;22:1027-34.
18. Menani JV, De Luca LA Jr, Thunhorst RL, Johnson AK. Hindbrain serotonin and the rapid induction of sodium appetite. Am J Physiol Regul Integr Comp Physiol 2000;279:R126-31.
19. Fitch GK, Weiss ML. Activation of renal afferent pathways following furosemide treatment. II. Effect of angiotensin blockade. Brain Res 2000;861:377-89.
20. Furtado D. Effect of chlorothiazide and furosemide diuresis on in vivo growth of Staphylococcus aureus in kidneys of mice. Invest Urol 1976;13:414-7.
21. Obika LF, Amurawaiye BS, Etok-Akpan E, Oduleye SO. Effect of frusemide on urinary kallikrein excretion in the conscious rat: influence of adrenalectomy and DOCA treatment. Pharmacol Res Commun 1988;20:49-59.
22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
23. Davis GA, Chandler MH. Comparison of creatinine clearance estimation methods in patients with trauma. Am J Health Syst Pharm 1996;53:1028-32.
24. Ponto LL, Schoenwald RD. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (part I). Clin Pharmacokinet 1990;18:381-408.
25. Asso D. Physiology and psychology of the normal menstrual cycle. In: Brush MG, Goudsmit EM, eds. Functional disorders of the menstrual cycle. Toronto: John Wiley and Sons, 1988:15-36.
26. Walker SE, Coons CE, DeAngelis C. Continuous subcutaneous infusion (CSCI) of narcotics for the treatment of cancer pain: a guide to CSCI for pharmacists. Department of Pharmacy, Sunnybrook Medical Centre and Toronto Bayview Regional Cancer Centre. Markham, Ontario: Knoll Pharmaceuticals Canada, 1988:8.